Vir Biotechnology reported that its monthly subcutaneous combination of elebsiran and tobevibart for chronic hepatitis delta met all primary and key secondary endpoints in the pivotal Phase 3 ECLIPSE ...
Source LinkVir Biotechnology reported that its monthly subcutaneous combination of elebsiran and tobevibart for chronic hepatitis delta met all primary and key secondary endpoints in the pivotal Phase 3 ECLIPSE ...
Source Link
Comments